256 related articles for article (PubMed ID: 16979660)
1. Structural basis of interaction between urokinase-type plasminogen activator and its receptor.
Barinka C; Parry G; Callahan J; Shaw DE; Kuo A; Bdeir K; Cines DB; Mazar A; Lubkowski J
J Mol Biol; 2006 Oct; 363(2):482-95. PubMed ID: 16979660
[TBL] [Abstract][Full Text] [Related]
2. Systematic mutational analysis of the receptor-binding region of the human urokinase-type plasminogen activator.
Magdolen V; Rettenberger P; Koppitz M; Goretzki L; Kessler H; Weidle UH; König B; Graeff H; Schmitt M; Wilhelm O
Eur J Biochem; 1996 May; 237(3):743-51. PubMed ID: 8647121
[TBL] [Abstract][Full Text] [Related]
3. Ligand binding regions in the receptor for urokinase-type plasminogen activator.
Liang OD; Chavakis T; Kanse SM; Preissner KT
J Biol Chem; 2001 Aug; 276(31):28946-53. PubMed ID: 11501527
[TBL] [Abstract][Full Text] [Related]
4. Crystal structure of the urokinase receptor in a ligand-free form.
Xu X; Gårdsvoll H; Yuan C; Lin L; Ploug M; Huang M
J Mol Biol; 2012 Mar; 416(5):629-41. PubMed ID: 22285761
[TBL] [Abstract][Full Text] [Related]
5. Crystallization of soluble urokinase receptor (suPAR) in complex with urokinase amino-terminal fragment (1-143).
Huang M; Mazar AP; Parry G; Higazi AA; Kuo A; Cines DB
Acta Crystallogr D Biol Crystallogr; 2005 Jun; 61(Pt 6):697-700. PubMed ID: 15930623
[TBL] [Abstract][Full Text] [Related]
6. cDNA transfection of amino-terminal fragment of urokinase efficiently inhibits cancer cell invasion and metastasis.
Zhu F; Jia S; Xing G; Gao L; Zhang L; He F
DNA Cell Biol; 2001 May; 20(5):297-305. PubMed ID: 11410166
[TBL] [Abstract][Full Text] [Related]
7. Structure of human urokinase plasminogen activator in complex with its receptor.
Huai Q; Mazar AP; Kuo A; Parry GC; Shaw DE; Callahan J; Li Y; Yuan C; Bian C; Chen L; Furie B; Furie BC; Cines DB; Huang M
Science; 2006 Feb; 311(5761):656-9. PubMed ID: 16456079
[TBL] [Abstract][Full Text] [Related]
8. A competitive chromogenic assay to study the functional interaction of urokinase-type plasminogen activator with its receptor.
Rettenberger P; Wilhelm O; Oi H; Weidle UH; Goretzki L; Koppitz M; Lottspeich F; König B; Pessara U; Kramer MD
Biol Chem Hoppe Seyler; 1995 Oct; 376(10):587-94. PubMed ID: 8590627
[TBL] [Abstract][Full Text] [Related]
9. Structure-function relationships in the interaction between the urokinase-type plasminogen activator and its receptor.
Ploug M
Curr Pharm Des; 2003; 9(19):1499-528. PubMed ID: 12871065
[TBL] [Abstract][Full Text] [Related]
10. Functional analysis of the cellular receptor for urokinase in plasminogen activation. Receptor binding has no influence on the zymogenic nature of pro-urokinase.
Ellis V
J Biol Chem; 1996 Jun; 271(25):14779-84. PubMed ID: 8662951
[TBL] [Abstract][Full Text] [Related]
11. Amino-terminal fragment of urokinase inhibits tumor cell invasion in vitro and in vivo: respective contribution of the urokinase plasminogen activator receptor-dependent or -independent pathway.
Li H; Soria C; Griscelli F; Opolon P; Soria J; Yeh P; Legrand C; Vannier JP; Belin D; Perricaudet M; Lu H
Hum Gene Ther; 2005 Oct; 16(10):1157-67. PubMed ID: 16218777
[TBL] [Abstract][Full Text] [Related]
12. Crystal structure of the human urokinase plasminogen activator receptor bound to an antagonist peptide.
Llinas P; Le Du MH; Gårdsvoll H; Danø K; Ploug M; Gilquin B; Stura EA; Ménez A
EMBO J; 2005 May; 24(9):1655-63. PubMed ID: 15861141
[TBL] [Abstract][Full Text] [Related]
13. Cyclo19,31[D-Cys19]-uPA19-31 is a potent competitive antagonist of the interaction of urokinase-type plasminogen activator with its receptor (CD87).
Magdolen V; Bürgle M; de Prada NA; Schmiedeberg N; Riemer C; Schroeck F; Kellermann J; Degitz K; Wilhelm OG; Schmitt M; Kessler H
Biol Chem; 2001 Aug; 382(8):1197-205. PubMed ID: 11592401
[TBL] [Abstract][Full Text] [Related]
14. Ab initio molecular orbital calculations on specific interactions between urokinase-type plasminogen activator and its receptor.
Nagase K; Kobayashi H; Yoshikawa E; Kurita N
J Mol Graph Model; 2009 Aug; 28(1):46-53. PubMed ID: 19403319
[TBL] [Abstract][Full Text] [Related]
15. Intermolecular contact regions in urokinase plasminogen activator receptor.
Liang OD; Bdeir K; Matz RL; Chavakis T; Preissner KT
J Biochem; 2003 Nov; 134(5):661-6. PubMed ID: 14688231
[TBL] [Abstract][Full Text] [Related]
16. Binding of human urokinase-type plasminogen activator to its receptor: residues involved in species specificity and binding.
Quax PH; Grimbergen JM; Lansink M; Bakker AH; Blatter MC; Belin D; van Hinsbergh VW; Verheijen JH
Arterioscler Thromb Vasc Biol; 1998 May; 18(5):693-701. PubMed ID: 9598826
[TBL] [Abstract][Full Text] [Related]
17. Photoaffinity labeling of the human receptor for urokinase-type plasminogen activator using a decapeptide antagonist. Evidence for a composite ligand-binding site and a short interdomain separation.
Ploug M; Ostergaard S; Hansen LB; Holm A; Danø K
Biochemistry; 1998 Mar; 37(11):3612-22. PubMed ID: 9521680
[TBL] [Abstract][Full Text] [Related]
18. Structural investigations of recombinant urokinase growth factor-like domain.
Beloglazova IB; Beabealashvilli RSh; Gursky YG; Bocharov EV; Mineev KS; Parfenova EV; Tkachuk VA
Biochemistry (Mosc); 2013 May; 78(5):517-30. PubMed ID: 23848154
[TBL] [Abstract][Full Text] [Related]
19. The effects of amino-acid mutations on specific interactions between urokinase-type plasminogen activator and its receptor: Ab initio molecular orbital calculations.
Tsuji S; Kasumi T; Nagase K; Yoshikawa E; Kobayashi H; Kurita N
J Mol Graph Model; 2011 Aug; 29(8):975-84. PubMed ID: 21605990
[TBL] [Abstract][Full Text] [Related]
20. Vitronectin concentrates proteolytic activity on the cell surface and extracellular matrix by trapping soluble urokinase receptor-urokinase complexes.
Chavakis T; Kanse SM; Yutzy B; Lijnen HR; Preissner KT
Blood; 1998 Apr; 91(7):2305-12. PubMed ID: 9516128
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
